Everything below concerns visceral adipose tissue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Since almost all food products are packed in some fashion, food packaging is both fundamental and pervasive. Additionally, by enabling the creation and standardization of brands, it provides the opportunity to realize significant advertising, extensive distribution, and mass merchandising. Therefore, a distinction between the various types (or levels) of packaging needs to be made.
=== Vitrification === Vitrification is a flash-freezing (ultra-rapid cooling) process that helps to prevent the formation of ice crystals and helps prevent cryopreservation damage. Researchers Greg Fahy and William F. Rall helped to introduce vitrification to reproductive cryopreservation in the mid-1980s. As of 2000, researchers claim vitrification provides the benefits of cryopreservation without damage due to ice crystal formation. The situation became more complex with the development of tissue engineering as both cells and biomaterials need to remain ice-free to preserve high cell viability and functions, integrity of constructs and structure of biomaterials. Vitrification of tissue engineered constructs was first reported by Lilia Kuleshova, who also was the first scientist to achieve vitrification of oocytes, which resulted in live birth in 1999. For clinical cryopreservation, vitrification usually requires the addition of cryoprotectants before cooling. Cryoprotectants are macromolecules added to the freezing medium to protect cells from the detrimental effects of intracellular ice crystal formation or from the solution effects, during the process of freezing and thawing. They permit a higher degree of cell survival during freezing, to lower the freezing point, to protect cell membrane from freeze-related injury. Cryoprotectants have high solubility, low toxicity at high concentrations, low molecular weight and the ability to interact with water via hydrogen bonding. Instead of crystallizing, the syrupy solution becomes an amorphous ice—it vitrifies.
Travellers require a biometric passport to use SmartGate as it uses information from the passport (such as photograph, name and date of birth) and in the respective countries' databases (i.e. banned travellers database) to decide whether to grant entry or departure from Australia or to generate a referral to a customs agent. These checks would otherwise require manual processing by a human, which is time-consuming, costly, and potentially error-prone. UK and Ireland: ePassport gates in the UK and Ireland are operated by the UK Border Force and the Irish Naturalisation and Immigration Service, and are located at immigration checkpoints in the arrival halls of some airports across both countries, offering an alternative to using desks staffed by immigration officers. The gates use a facial recognition system to verify the user's identity by comparing their facial features to those recorded in the photograph stored on the chip of their biometric passport. British citizens, European Economic Area citizens and citizens of Australia, Canada, Japan, New Zealand, Singapore, South Korea, Taiwan and the United States as well as Chinese citizens of Hong Kong who are enrolled in the Registered Traveller Service, can use ePassport gates at 14 ports of entry in the United Kingdom provided that they are aged either 18 and over or 12 and over, travelling with an adult and holding valid biometric passports.
phosphate Any chemical species or functional group derived from phosphoric acid (H3PO4) by the removal of one or more protons (H+); the completely ionized form, [PO4]3−, consists of a single, central phosphorus atom covalently bonded to four oxygen atoms via three single bonds and one double bond. Phosphates are abundant and ubiquitous in biological systems, where they occur either as free anions in solution, known as inorganic phosphates and symbolized Pi, or bonded to organic molecules via ester bonds. The huge diversity of organophosphate compounds includes all nucleotides, whose phosphate groups are linked by phosphodiester bonds to form the structural backbones of long nucleotide chains such as DNA and RNA, and the high-energy diphosphate and triphosphate substituents of individual nucleotides such as ADP and ATP serve as essential energy carriers in all cells. Phospholipids are major components of most membranes. Enzymes known as kinases and phosphatases catalyze the addition and removal of phosphate groups to and from these and other biomolecules.
Sources: en.wikipedia.org
There are ten official universities in Israel, of which nine are public, a few dozen colleges, and about a dozen foreign university extensions. The Council for Higher Education in Israel supervises all of these institutions academically. Only a university, not a college, can issue doctoral degrees in Israel.
Corals' many colors give it appeal for necklaces and other jewelry. Intensely red coral is prized as a gemstone. Sometimes called fire coral, it is not the same as fire coral. Red coral is very rare because of overharvesting. In general, it is inadvisable to give coral as gifts since they are in decline from stressors like climate change, pollution, and unsustainable fishing. Always considered a precious mineral, "the Chinese have long associated red coral with auspiciousness and longevity because of its color and its resemblance to deer antlers (so by association, virtue, long life, and high rank". It reached its height of popularity during the Manchu or Qing Dynasty (1644–1911) when it was almost exclusively reserved for the emperor's use either in the form of coral beads (often combined with pearls) for court jewelry or as decorative Penjing (decorative miniature mineral trees). Coral was known as shanhu in Chinese. The "early-modern 'coral network' [began in] the Mediterranean Sea [and found its way] to Qing China via the English East India Company". There were strict rules regarding its use in a code established by the Qianlong Emperor in 1759. By the middle of the 19th century, "coral fisheries" existed in the Mediterranean, the Red Sea, Persian Gulf and elsewhere. An instrument used to retrieve the coral consisted of two beams of heavy wood attached to each other at right angles. Heavy stones were added to make the apparatus sink and netting was attached beneath the device.
=== Microstructures === The interplay of molecular scale mechanisms and hierarchical surface structures is known to result in high levels of static friction and bonding between pairs of surfaces. Technologically advanced adhesive devices sometimes make use of microstructures on surfaces, such as tightly packed periodic posts. These are biomimetic technologies inspired by the adhesive abilities of the feet of various arthropods and vertebrates (most notably, geckos). By intermixing periodic breaks into smooth, adhesive surfaces, the interface acquires valuable crack-arresting properties. Because crack initiation requires much greater stress than does crack propagation, surfaces like these are much harder to separate, as a new crack has to be restarted every time the next individual microstructure is reached.
== External links == Overview at colostate.edu Archived 2017-05-19 at the Wayback Machine Nosek TM. "Section 6/6ch4/s6ch4_14". Essentials of Human Physiology. Archived from the original on 2016-03-24.
=== No development reported === Adapalene/minocycline (FCD-105) – combination of adapalene (retinoid) and minocycline (tetracycline antibiotic) Auriclosene (AgaDerm; AgaNase; AL-46383A; CD-07223; DCDMT; NVC-422) – aganocide compound and antimicrobial Bermekimab (CA-18C3; CV-18C3; Hutruo; JNJ-77474462; MAB-p1; RA-18C3; T2-18C3; Xilonix) – monoclonal antibody against interleukin-1α BOS-356 (GSK-3008356) – diacylglycerol O-acyltransferase inhibitor Brilacidin (PMX-30063) – host defense protein (HDP) mimetic antibiotic Carbamide peroxide topical (E-0301) – disinfectant and bleaching agent CJM-112 – IL17A and IL17F inhibitor Clindamycin/tretinoin – combination of clindamycin (lincosamide antibiotic) and tretinoin (retinoid) Clindamycin/tretinoin – combination of clindamycin (lincosamide antibiotic) and tretinoin (retinoid) DMT-200 (DMT-210; DMT-220; SIG-990) – isoprenylcysteine analogue and various actions Estradiol valerate/dienogest (Climodien; Climodiène; Klimodien; Lafamme) – combination of estradiol valerate (estrogen) and dienogest (progestogen) Ethinylestradiol/chlormadinone acetate (Balianca; Belara; GRT4248) – combination of ethinylestradiol (estrogen) and chlormadinone acetate (progestogen) and a combined oral contraceptive Ethinylestradiol/drospirenone (Petibelle; SH-470; Yasmin; ZK-30595) – combination of ethinylestradiol (estrogen) and drospirenone (progestogen) GSK-1940029 – stearoyl-CoA desaturase inhibitor GT-20029 (AR-PROTAC) – androgen receptor degradation enhancer IP10-C8 – CD13 antigen inhibitor and dipeptidyl peptidase 4 (DPP4) inhibitor Minocycline extended release (Emrosi; Ximino) – tetracycline antibiotic Minocycline topical (HY01) – tetracycline antibiotic MTC-896 – melanocortin receptor antagonist Nitric oxide (Enovid; FabiSpray; NORS-0791; NORS-1002; NORS-2791; NORS-4002; NORS-6491; NORS) – nitric oxide donor ORG-101 (acne vulgaris vaccine; ORI-001; ORI-A-ce001) – immunostimulant, vaccine Radezolid (RX-01667; Rx-01_667; RX-103; RX-1741) – oxazolidone antibiotic Research programme: antimicrobial therapies - NovaBiotics – cell membrane permeability enhancers Research programme: synthetic cannabinoid therapeutics - Claritas Pharmaceuticals – cannabinoids (cannabinoid receptor modulators) Research programme: therapeutic antibody fragments - Kuur Therapeutics – various actions Silver dihydrogen citrate (SDC; Axenohl) – antiseptic/antibacterial Tazarotene topical (DFD-03) – retinoid X receptor agonist
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.